Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.050
+0.050 (+1.00%)
Streaming Delayed Price
Updated: 12:13 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Expert Ratings for Editas Medicine
May 09, 2022
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Editas Medicine: Q1 Earnings Insights
May 04, 2022
Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 28, 2022
Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to...
Via
Benzinga
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
April 26, 2022
The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia from leading...
Via
Benzinga
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
March 01, 2022
The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
27 Stocks Moving in Monday's Pre-Market Session
March 01, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6...
Via
Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
February 28, 2022
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.
Via
Investor's Business Daily
Expert Ratings For Editas Medicine
February 25, 2022
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Editas Suddenly Terminates Chief Medical Officer Without An Explanation
February 08, 2022
Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.
Via
Benzinga
51 Biggest Movers From Yesterday
February 09, 2022
Also check out this: Apple And 3 Other Stocks Sold By Insiders Losers SelectQuote, Inc. (NYSE: SLQT) shares tumbled 47.3% to close at $3.44 on Tuesday after the company...
Via
Benzinga
35 Stocks Moving In Tuesday's Mid-Day Session
February 08, 2022
Gainers Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) climbed 56.1% to $3.45 following...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 08, 2022
Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $59...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 08, 2022
Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
21 Stocks Moving in Tuesday's Pre-Market Session
February 08, 2022
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out this: Moderna And 4 Other Stocks Sold By...
Via
Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
January 10, 2022
The companies hope to cure diseases of the liver, muscle and central nervous system.
Via
Investor's Business Daily
Stocks Hitting New 52-Week Lows Today
January 03, 2022
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...
Via
Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.
Via
InvestorPlace
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
December 13, 2021
Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR).
Via
InvestorPlace
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
December 13, 2021
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937.
Via
InvestorPlace
EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today
December 13, 2021
After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.
Via
InvestorPlace
22 Stocks Moving in Monday's Pre-Market Session
December 13, 2021
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose...
Via
Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
November 15, 2021
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
Via
Talk Markets
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
November 08, 2021
EDIT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.